Pyrotinib after breast cancer therapy for HER2-positive early disease
Treatments studied
Part of Cancer clinical trials.
This trial studies whether adding pyrotinib after standard treatment helps prevent breast cancer from coming back in people with HER2-positive early-stage breast cancer. You may be eligible if you finished chemotherapy plus trastuzumab and still had signs of cancer in the tissue removed during surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old and were born female.
- Your breast cancer is HER2-positive and was early stage (Stage IIA–III), not metastatic.
- You completed neoadjuvant treatment (chemotherapy plus trastuzumab), and surgery showed leftover invasive cancer in the breast or nearby lymph nodes.
- Your heart function is good enough for the study (LVEF at least 50%) and you meet key blood test and organ-function limits.
- Your last trastuzumab dose was within 1 year of the trial start, and you have not had other recent clinical-trial treatment in the last 4 weeks.
- You must be able to swallow tablets and not have major stomach or absorption problems.
- You must not have taken other anti-HER2 pills/targeted drugs like pyrotinib, lapatinib, or neratinib before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking pyrotinib continuously or intermittently can help people with HER2-positive advanced breast cancer that has spread. It is for those who have already received prior treatment for their advanced disease.
This Phase 3 trial tests whether continuing or pausing the anti-HER2 medicine pyrotinib after surgery can lower the chance that invasive HER2-positive breast cancer comes back. It may help people who have recently finished trastuzumab or T-DM1 and are well enough to take tablets.
This trial tests whether giving a combination of two targeted drugs (pyrotinib and trastuzumab) along with standard chemotherapy before surgery can work better for HER2-positive breast cancer. It is for women whose cancer has not spread to distant organs and who have not yet had treatment for their cancer.
This trial tests a targeted drug called pyrotinib for women with HER2-positive early or locally advanced breast cancer. It aims to see if adding this treatment before surgery improves outcomes.
This Phase 2 trial tests pyrotinib, a HER2-targeted cancer medicine, in people with high-risk, HER2-positive breast cancer after surgery. It aims to lower the chance the cancer comes back, especially when standard treatment did not fully clear the tumor.
This trial tests whether adding pyrotinib to trastuzumab after surgery can reduce breast cancer coming back in people with HER2-positive, early-stage breast cancer. It may help some patients by improving treatment effectiveness, but it also requires meeting specific heart, lab, and health criteria.
Hear when a new Locally Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.